X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
X4 Pharmaceuticals (Nasdaq: XFOR) announced it will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 21, 2023. A conference call will follow at 9:00 a.m. ET to discuss these results and recent business highlights. X4 is focused on developing mavorixafor, a novel therapy for chronic neutropenic disorders, including WHIM syndrome. The company is preparing for a U.S. regulatory submission after positive Phase 3 trial results. The investor webcast will be available on X4's website post-call.
- X4 plans to submit for U.S. regulatory approval for mavorixafor following positive Phase 3 trial results.
- The company is advancing its lead candidate in multiple clinical trials.
- None.
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.
The company will host a conference call and webcast on the same day at 9:00 a.m. ET to discuss these financial results and recent business highlights. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-576-4098 internationally, followed by the conference ID: 10020997. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. Following announcement of positive top-line data from our global, pivotal, 4WHIM Phase 3 clinical trial, we are currently preparing a U.S. regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. We are also currently evaluting mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial of mavorixafor in people with congenital, idiopathic, or cyclic neutropenia. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Contacts:
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Cherilyn Cecchini, M.D. (media)
LifeSci Communications
ccecchini@lifescicomms.com
FAQ
When will X4 Pharmaceuticals announce its Q4 2022 financial results?
What is mavorixafor and its significance for X4 Pharmaceuticals?
How can I access the conference call for X4 Pharmaceuticals' financial results?
Where can I find the webcast of the X4 Pharmaceuticals conference call?
